Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.54 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.54 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.47 |
| ▸ | DRD1 | P21728 | 5/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.45 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.45 |
| ▸ | RYR2 | Q92736 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24489998 | 0.89 | SLC6A2 (0.62) | SLC6A2SLC6A4SLC6A3TAS2R14MTNR1B | |
| SCHEMBL22461555 | 0.89 | SLC6A2 (0.62) | SLC6A2SLC6A4SLC6A3TAS2R14MTNR1B | |
| SCHEMBL10345414 | 0.87 | SLC6A2 (0.58) | SLC6A2SLC6A4SLC6A3TAS2R14DRD1 | |
| SCHEMBL18085044 | 0.83 | SLC6A2 (0.54) | SLC6A2SLC6A4SLC6A3TAS2R14DRD1 | |
| SCHEMBL22461131 | 0.83 | MAPT (0.57) | SLC6A2SLC6A4SLC6A3DRD1HTR2A | |
| SCHEMBL22461133 | 0.83 | MAPT (0.57) | SLC6A2SLC6A4SLC6A3DRD1HTR2A | |
| SCHEMBL24490097 | 0.83 | SLC6A4 (0.62) | SLC6A2SLC6A4SLC6A3RYR2 | |
| SCHEMBL24490020 | 0.83 | SLC6A4 (0.62) | SLC6A2SLC6A4SLC6A3RYR2 | |
| SCHEMBL22461454 | 0.78 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL22461450 | 0.78 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160272572-A1 | ADENYLYL CYCLASE INHIBITORS FOR NEUROPATHIC AND INFLAMMATORY PAIN | PURDUE RESEARCH FOUNDATION | 2016-09-22 | — | — | US | disclosed |
| US-20160272572-A1 | ADENYLYL CYCLASE INHIBITORS FOR NEUROPATHIC AND INFLAMMATORY PAIN | PURDUE RESEARCH FOUNDATION | 2016-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160272572-A1 | ADENYLYL CYCLASE INHIBITORS FOR NEUROPATHIC AND INFLAMMATORY PAIN | ADCY1, ADCY2, ADCY5 | SLC6A2 1451/4885SLC6A4 1854/4885SLC6A3 1919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.